stockmarketproxy
/
MRNANasdaq SEC EDGAR

Moderna, Inc.

Biological Products, (No Diagnostic Substances)·CAMBRIDGE, MA·FY end 12/31·CIK 1682852
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.9B$3.2B$6.8B$19.3B$18.5B
Gross Profit——————
Operating Income-$3.1B-$3.9B-$4.2B$9.4B$13.3B
Net Income-$2.8B-$3.6B-$4.7B$8.4B$12.2B
Operating CF-$1.9B-$3.0B-$3.1B$5.0B$13.6B
Capex$192.0M$1.1B$707.0M$400.0M$284.0M
Free Cash Flow-$2.1B-$4.1B-$3.8B$4.6B$13.3B
Buybacks$2.0M$0$1.2B$3.3B$857.0M
Dividends——————
Gross Margin——————
Operating Margin-158.1%-121.9%-61.9%48.9%72.0%
Net Margin-145.2%-110.0%-68.8%43.4%66.1%
FCF Margin-106.2%-125.3%-55.9%23.8%72.2%
R&D / Revenue161.1%140.4%70.8%17.1%10.8%
Effective Tax-2.0%1.3%-19.6%12.7%8.2%
Debt / Equity0.07—————
Buybacks / FCF-0.1%0.0%-30.1%72.7%6.4%

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
MRNA
89:1
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
MRNA
$0M
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
MRNA
-145.2%
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%